Resolution of Infliximab-induced Palmar Pustular Psoriasis (PPP) After Switching to Biosimilar Infliximab-DYYB

Inflamm Bowel Dis. 2019 Aug 20;25(9):e103. doi: 10.1093/ibd/izz117.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Biosimilar Pharmaceuticals / therapeutic use*
  • Dermatologic Agents / adverse effects*
  • Drug Substitution / methods*
  • Female
  • Humans
  • Infliximab / adverse effects*
  • Prognosis
  • Psoriasis / chemically induced
  • Psoriasis / pathology
  • Psoriasis / prevention & control*

Substances

  • Biosimilar Pharmaceuticals
  • Dermatologic Agents
  • Infliximab